摘要 |
The present invention relates to a pharmaceutical composition for the treatment of MCP-1 mediated inflammatory diseases, comprising 1-benzyl-3-hydroxymethylindazole presented by formula (I), a pressure lowering agent selected from ACE-inhibitors, ARBs and CCBs, and/or a cholesterol lowering agent selected from statin derivatives or any pharmaceutically acceptable salt thereof and ester and one pharmaceutically acceptable carrier, wherein said ACE-inhibitor is selected from the group consisting of enalapril, lisinopril, ramipril and perindopril; said ARB is selected from the group consisting of candesartan, irbesartan, losartan and valsartan; said CCB is selected from the group consisting of amlodipine, lacidipine, nifedipine and verapamil; and said statin derivative is selected from the group consisting of lovastatin, pravastatin and simvastatin. The combination showed an additive and synergistic activity in reducing MCP-1 levels, thus significantly improving inflammatory response inhibition and consequently reducing complications occurring in patients suffering from inflammatory diseases. |